| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H13BrCl2FN3O4S |
| Molecular Weight | 573.219 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC(Cl)=C(NC(=O)CC2=CC=C(Br)C(OC3=CC(=CC(Cl)=C3)C#N)=C2F)C=C1
InChI
InChIKey=SBUUICLVCQQMFP-UHFFFAOYSA-N
InChI=1S/C21H13BrCl2FN3O4S/c22-16-3-1-12(20(25)21(16)32-14-6-11(10-26)5-13(23)8-14)7-19(29)28-18-4-2-15(9-17(18)24)33(27,30)31/h1-6,8-9H,7H2,(H,28,29)(H2,27,30,31)
| Molecular Formula | C21H13BrCl2FN3O4S |
| Molecular Weight | 573.219 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
R-1206 (also known as Elsulfavirine) is a phenylacetamide derivative patented by Roche Palo Alto LLC as non-nucleoside reverse transcriptase inhibitor (NNRTI) for treating retroviral infections. R-1206 is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. The antiviral activity of R-1206 is broad, with activity demonstrated towards various viral strains and clinical isolates of HIV, including those resistant to other NNRTIs. Furthermore, R-1206 was associated with a low probability of cross-resistance or resistance development, and a high genetic barrier to the development of resistant drug mutations. In clinical trials, R-1206 20 and 40 mg demonstrated superiority to efavirenz in terms of the effectiveness to reduce the level of viral load to 400 copies/mL after 12 weeks of therapy. R-1206 20 mg once daily is generally well tolerated in ART-naive HIV-1 infected patients.
